Drug intelligence / Profile preview

EW-7195

Development stage: Preclinical
Lead developer: Ewha Womans University
Modality: Small Molecules

Overview

EW-7195: sourced facts only. name: "EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung." [1] target: "In this study, the authors examined a novel small molecule inhibitor of ALK5," [1] developer: "College of Pharmacy, Ewha Womans University, Seodaemun-gu, Seoul, Republic of Korea." [1] stage: "Furthermore, in xenografted Balb/c and MMTV/cNeu mice, EW-7195 inhibited metastasis to lung from breast tumours." [1] modality: "In this study, the authors examined a novel small molecule inhibitor of ALK5," [1]

Targets

TGFBR1

Beyond the preview

Go deeper on EW-7195.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EW-7195.